InCellDx develops cell-based instruments and in-situ hybridization methods to quantify protein and gene expression within intact cells, enabling measurement by distinct cell type for improved diagnosis and disease localization. The company targets detection and monitoring of life‑threatening conditions including cervical cancer, breast cancer, HIV/AIDS, hepatitis and transplant rejection. Its patented technology has been adapted by GenPath for quantification of E6/E7 mRNA in HPV. In conjunction with the investment, BRLI’s GenPath Women’s Health developed and launched a test called GenCerv based on InCellDx’s HPV mRNA quantification technology. The company is led by founder and CEO Bruce Patterson, MD, and is based in Menlo Park, California. IncellDx develops molecular diagnostic products, including an E6/E7 mRNA test called HPV OncoTect intended to detect and quantify oncogenes that drive progression to cervical cancer. The company plans to use recently raised funds to advance commercialization of its product portfolio and to start a U.S. clinical trial for HPV OncoTect. IncellDx positions HPV OncoTect as addressing the lack of specificity in existing U.S. high-risk HPV screening products. The article cites the U.S. high-risk HPV testing market as roughly $300M and growing at about 14% annually. The company is based in Menlo Park, California. The investors in the reported round were not disclosed.

Total raised

$9M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2012